SEARCH:   Advanced

Blood, 1 December 2005, Vol. 106, No. 12, pp. 3785-3790. Prepublished online as a Blood First Edition Paper on August 18, 2005; DOI 10.1182/blood-2005-05-2056. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-05-2056v1 106/12/3785    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kim, T. M. Articles by Kim, N. K. Search for Related Content PubMed PubMed Citation Articles by Kim, T. M. Articles by Kim, N. K. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type Tae Min Kim, Yeon Hee Park, Sang-Yoon Lee, Ji-Hoon Kim, Dong-Wan Kim, Seock-Ah Im, Tae-You Kim, Chul Woo Kim, Dae Seog Heo, Yung-Jue Bang, Kee-Hyun Chang, and Noe Kyeong Kim From the Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Korea; and Departments of Radiology and Pathology, Seoul National University College of Medicine, Seoul, Korea. This study was launched to determine the prognostic significance of local tumor invasiveness (LTI) in 114 patients diagnosed with stage IE/IIE extranodal natural killer (NK)/T-cell lymphoma, nasal type (NTCL). LTI was defined as bony invasion or destruction or tumor invasion of the skin. Complete remission (CR), overall survival (OS), and disease-free survival (DFS) were compared between each group according to LTI, Ann Arbor stage, and International Prognostic Index (IPI). LTI was observed in 23 patients. Using multivariate analysis, factors associated with low probability of CR were the presence of LTI (P < .001), the presence of B symptoms (P = .003), and single-modality chemotherapy (P = .045). The presence of LTI (relative risk [RR] = 8.4, 95% confidence interval [CI] 3.9-17.9; P < .001) and high IPI score (RR = 2.8, 95% CI 1.2-6.8; P = .019) were also predictive of OS. The presence of LTI (RR = 7.3, 95% CI 3.2-16.5; P < .001) was an independently significant factor for reduced DFS. Ann Arbor staging system did not predict CR, OS, or DFS but IPI did have predictive power with regard to survival outcome. LTI is the most important prognostic factor in predicting low probability of CR and reduced OS and DFS in nasal stage IE/IIE NTCL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. J. Kim, S. Y. Oh, J. Y. Hong, M. H. Chang, D. H. Lee, J. Huh, Y. H. Ko, Y. C. Ahn, H.-J. Kim, C. Suh, et al. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann. Onc., October 22, 2009; (2009) mdp412v1. [Abstract] [Full Text] [PDF] R. Suzuki, J. Suzumiya, M. Yamaguchi, S. Nakamura, J. Kameoka, H. Kojima, M. Abe, T. Kinoshita, T. Yoshino, K. Iwatsuki, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type Ann. Onc., October 22, 2009; (2009) mdp418v1. [Abstract] [Full Text] [PDF] W. Y. Kim, Y. K. Jeon, T. M. Kim, J. E. Kim, Y. A. Kim, S.-H. Lee, D.-W. Kim, D. S. Heo, and C.-W. Kim Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma Ann. Onc., October 1, 2009; 20(10): 1688 - 1696. [Abstract] [Full Text] [PDF] X. Liu, B. Wang, X. Ma, and Y. Guo NF-{kappa}B Activation Through the Alternative Pathway Correlates with Chemoresistance and Poor Survival in Extranodal NK/T-cell Lymphoma, Nasal Type Jpn. J. Clin. Oncol., July 1, 2009; 39(7): 418 - 424. [Abstract] [Full Text] [PDF] R. Suzuki, J. Suzumiya, and K. Oshimi Differences between nasal and extranasal NK/T-cell lymphoma Blood, June 11, 2009; 113(24): 6260 - 6261. [Full Text] [PDF] Y.-X. Li, Q.-F. Liu, H. Fang, S.-N. Qi, H. Wang, W.-H. Wang, Y.-W. Song, J. Lu, J. Jin, S.-L. Wang, et al. Variable Clinical Presentations of Nasal and Waldeyer Ring Natural Killer/T-Cell Lymphoma Clin. Cancer Res., April 15, 2009; 15(8): 2905 - 2912. [Abstract] [Full Text] [PDF] B.-S. Kim, D.-W. Kim, S.-A. Im, C. W. Kim, T.-Y. Kim, S.-S. Yoon, D. S. Heo, Y.-J. Bang, S. Park, B. K. Kim, et al. Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone Ann. Onc., January 1, 2009; 20(1): 121 - 128. [Abstract] [Full Text] [PDF] C. Suh, Y.-K. Kang, J.-L. Roh, M. R. Kim, J. S. Kim, J. Huh, J. H. Lee, Y. J. Jang, and B.-J. Lee Prognostic Value of Tumor 18F-FDG Uptake in Patients with Untreated Extranodal Natural Killer/T-Cell Lymphomas of the Head and Neck J. Nucl. Med., November 1, 2008; 49(11): 1783 - 1789. [Abstract] [Full Text] [PDF] Y.-X. Li, H. Fang, Q.-F. Liu, J. Lu, S.-N. Qi, H. Wang, J. Jin, W.-H. Wang, Y.-P. Liu, Y.-W. Song, et al. Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring Blood, October 15, 2008; 112(8): 3057 - 3064. [Abstract] [Full Text] [PDF] T. M. Kim, S. -Y. Lee, Y. K. Jeon, B. -Y. Ryoo, G. J. Cho, Y. S. Hong, H. J. Kim, S.-Y. Kim, C. S. Kim, S. Kim, et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group Ann. Onc., August 1, 2008; 19(8): 1477 - 1484. [Abstract] [Full Text] [PDF] S. Kim, B. Kim, C. Choi, J Choi, I Kim, Y-H Lee, and J. Kim Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type Ann. Onc., August 1, 2007; 18(8): 1382 - 1387. [Abstract] [Full Text] [PDF] C. Bossard, K. Belhadj, F. Reyes, N. Martin-Garcia, F. Berger, J. A. Kummer, J. Briere, A.-C. Baglin, S. Cheze, J. Bosq, et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials Blood, March 1, 2007; 109(5): 2183 - 2189. [Abstract] [Full Text] [PDF] J. Lee, C. Suh, Y. H. Park, Y. H. Ko, S. M. Bang, J. H. Lee, D. H. Lee, J. Huh, S. Y. Oh, H.-C. Kwon, et al. Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study J. Clin. Oncol., February 1, 2006; 24(4): 612 - 618. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020